

April 26, 2018



Synthetic Biologics to Report First Quarter 2018 Operational Highlights and Financial Results on May 8, 2018

-- Conference Call Scheduled for Tuesday, May 8, 2018 at 4:30 p.m. EDT

--

ROCKVILLE, Md., April 26, 2018 /PRNewswire/ -- [Synthetic Biologics, Inc.](http://www.syntheticbiologics.com) (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the Company intends to release its operational highlights and financial results for the quarter ended March 31, 2018 on Tuesday, May 8, 2018, and to host a conference call the same day at 4:30 p.m. EDT. The dial-in information for the call is as follows:




U.S. (toll free): 1-888-347-5280
International: +1 412-902-4280

Participants are asked to dial in 15 minutes before the start of the call to register. The call will also be webcast over the Internet at <https://www.webcaster4.com/Webcast/Page/1096/25579>. An archived replay of the call will be available for approximately ninety (90) days at the same URL, <https://www.webcaster4.com/Webcast/Page/1096/25579> beginning approximately one hour after the call's conclusion.

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE American: SYN) is a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients. The Company's lead candidates poised for Phase 3 development are: (1) SYN-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention of *C. difficile* infection (CDI), overgrowth of pathogenic organisms and the emergence of antimicrobial resistance (AMR), and (2) SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). The Company's preclinical pursuits include an oral formulation of the enzyme intestinal alkaline phosphatase (IAP) to treat both local GI and systemic diseases as well as monoclonal antibody therapies for the prevention and treatment of pertussis, and novel discovery stage biotherapeutics for the treatment of phenylketonuria (PKU). For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.

 View original content with multimedia <http://www.prnewswire.com/news-releases/synthetic-biologics-to-report-first-quarter-2018-operational-highlights-and-financial-results-on-may-8-2018-300636647.html>

SOURCE Synthetic Biologics, Inc.